What is claimed is:

1. A method for the prophylaxis or treatment of asthma, bronchospastic diseases characterized by airway hyperreactivity or lung inflammatory reaction characterized by increased eosinophilia comprising the administration of an active agent selected from the group consisting of CGRP, CGRP natural homologs, CGRP analogs, the analogs of CGRP's natural homologs, CGRP fragments, the fragments of CGRP's natural homologs, CGRP natural derivatives and the natural derivatives of CGRP's natural homologs.

2. The method of claim 1, wherein said administration is via a pulmonary route.

3. The method of claim 1, wherein said administration of said active agent is for the prophylaxis or treatment of asthma.

4. The method of claim 3, wherein said active agent is CGRP.

5. The method of claim 4, wherein said administration is via a pulmonary route.

6. The method of claim 3, wherein said active agent has a purity of at least about 95 to 98 %.

7. The method of claim 3, wherein said active agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, liquid or solid carrier.

8. The method of claim 7, wherein said composition is in a form suitable to be introduced into a mammal by providing an aerosol or

dry powder comprising said active agent for inhalation by said mammal.

9. The method of claim 1, wherein said administration of said active agent is for the prophylaxis or treatment of bronchospastic diseases characterized by airway hyperreactivity.

10. The method of claim 9, wherein said active agent is CGRP.

11. The method of claim 10, wherein said administration is via a pulmonary route.

12. The method of claim 9, wherein said active agent has a purity of at least about 95 to 98 %.

13. The method of claim 9, wherein said active agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, liquid or solid carrier.

14. The method of claim 13, wherein said composition is in a form suitable to be introduced into a mammal by providing an aerosol or dry powder comprising said active agent for inhalation by said mammal.

15. The method of claim 1, wherein said administration of said active agent is for the prophylaxis or treatment of lung inflammatory reaction characterized by increased eosinophilia.

16. The method of claim 15, wherein said active agent is CGRP.

17. The method of claim 16, wherein said administration is via a pulmonary route.

18. The method of claim 15, wherein said active agent has a purity of at least about 95 to 98 %.

19. The method of claim 15, wherein said active agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, liquid or solid carrier.

20. The method of claim 19, wherein said composition is in a form suitable to be introduced into a mammal by providing an aerosol or dry powder comprising said active agent for inhalation by said mammal.